Conference Coverage
Constraint-induced movement therapy may boost neuroplasticity in MS
For patients with asymmetric upper limb nonuse, the treatment “is highly successful for promoting increased use by the more-affected arm.”
Conference Coverage
Telerehabilitation may be effective in MS
Patients with MS may achieve equivalent benefits and increased cost savings with telerehabilitation, compared with outpatient rehabilitation.
Conference Coverage
No benefit of three commonly used medications for MS fatigue
These findings will hopefully encourage doctors to “think twice before prescribing these medications that could be harmful and have no clear...
Conference Coverage
Ofatumumab shows high elimination of disease activity in MS
The once-per-month self-injected therapy could offer an alternative to DMTs that require in-office infusion.
Conference Coverage
Natalizumab switch to moderate-efficacy DMT increases disability risk
“Patients transitioning from natalizumab to another high-efficacy therapy have better inflammatory and disability outcomes, compared with those...
Conference Coverage
High levels of air pollution linked to increased MS risk
“Countermeasures that cut air pollution can be important for public health, not only to reduce deaths related to cardiac and pulmonary diseases...
Conference Coverage
Natalizumab bests fingolimod for relapsing-remitting MS
More patients taking natalizumab versus fingolimod reached NEDA at one year.
Conference Coverage
Serum NfL in early MS can help predict clinical course
Higher serum NfL within 5 years of MS diagnosis carries a higher risk of long term-clinical disability and higher risk of developing progressive...
Conference Coverage
Initial high-efficacy MS therapy tied to less disability later
Conference Coverage
Cautionary findings on acquired immunodeficiency from anti-CD20 MS therapy
Clinicians are advised to monitor patients with MS much closer for signs of hypogammaglobulinemia and lymphopenia starting with year 2 on therapy...
Conference Coverage
Five-year siponimod data support early MS treatment
During an open-label extension, patients who initially received placebo before switching to siponimod were more likely to have confirmed...
Conference Coverage
Report details first case of PML with ocrelizumab alone
The first case of PML directly associated with ocrelizumab occurred in a 78-year-old male with primary progressive MS.
News
Database will collect data on COVID-19 in patients with MS
A registry is gathering information on patients throughout the United States with a view to understanding outcomes and improving treatment.
News
FDA removes pregnancy category C warning from certain MS medications
Labeling updates include more information on using certain MS drugs during pregnancy and breastfeeding.
News
FDA approves ozanimod for relapsing and secondary progressive forms of MS
It is the only approved sphingosine-1-phosphate receptor modulator with no requirement for genetic testing or label-based first-dose observation...
Conference Coverage
Teriflunomide increases the likelihood of achieving NEDA in relapsing-remitting MS
WEST PALM BEACH, FLA. – Teriflunomide decreases the risks of relapse, relapse resulting in hospital admission, and...
Conference Coverage
Manual dexterity may decline more rapidly in pediatric-onset MS
WEST PALM BEACH, FLA. – Age, sex, Patient-Determined Disease Steps, and multiple sclerosis type significantly affect...
Conference Coverage
-
Constraint-induced movement therapy may boost neuroplasticity in MS -
-
No benefit of three commonly used medications for MS fatigue -
Ofatumumab shows high elimination of disease activity in MS -
Natalizumab switch to moderate-efficacy DMT increases disability risk
Multimedia
Question 1 of 5